- Resource Centers
A new generic-industry joint venture linking New Jersey?based Amneal Pharmaceuticals and India?s Indoco Remedies will result in the marketing of at least 10 generic ophthalmic products in the United States.
Amneal?s role in the partnership will be to prepare and file abbreviated new drug applications for FDA approval and to exclusively market these products throughout the US pharmaceutical market. Indoco will be responsible for manufacturing the generics. Spokesmen for the 2 companies said that Indoco and Amneal have already begun to identify several more ophthalmic products to pursue, as well as other therapeutic categories and dosage forms.